Physician profile
Michael Eshaghian
NPI 1639297096
$35,492.52
in general payments reported to CMS, 2019-2025
23 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $259 · 2021: $238 · 2022: $540 · 2023: $419 · 2024: $15K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,200.00 |
| Food and Beverage | $993.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $33,200.00 | 2024-2025 | Bovine Collagen |
| Coopersurgical, INC. | $726.82 | 2019-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Abbvie INC. | $260.30 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $257.39 | 2019-2025 | |
| Organon LLC | $176.33 | 2021-2025 | Nexplanon |
| Lupin INC. | $128.86 | 2019-2020 | |
| Hologic Sales and Service, LLC | $109.88 | 2020-2024 | Thinprep 2000 Processor, Aptima |
| Allergan, INC. | $104.04 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $64.85 | 2021-2023 | |
| Amag Pharmaceuticals, INC. | $63.65 | 2019 | |
| Myovant Sciences INC. | $54.60 | 2021-2022 | |
| Pfizer INC. | $52.80 | 2022-2024 | |
| Merz North America, INC. | $48.50 | 2025 | |
| Smith+Nephew, INC. | $40.06 | 2025 | Stravix Pl |
| Embecta Corp. | $38.04 | 2023 | Bd Nano 2nd Gen Pen Needle |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $27.35 | 2021 | |
| Sumitomo Pharma America, INC. | $25.73 | 2023 | Myfembree |
| Roche Diagnostics Corporation | $24.86 | 2019 | |
| Shield Therapeutics INC | $22.51 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $18.25 | 2022 | |
| Merck Sharp & Dohme LLC | $17.31 | 2019 | |
| Cranial Technologies, INC | $15.35 | 2025 | Doc Band |
| Agile Therapeutics, INC. | $15.04 | 2024 | Twirla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eshaghian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.